]>
IRCT20171229038124N1 IRCT 2018-08-04 Ahvaz University of Medical Sciences Evaluation of the Donepezil and Rivastigmine co – administration on the cognitive deficits induced by EcT: A Randomized Double Blind Clinical Trial Evaluation of the Donepezil and Rivastigmine co – administration on the cognitive deficits induced by EcT: A Randomized Double Blind Clinical Trial 2017-11-22 anticipated 60 Complete https://irct.ir/trial/29862 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Table of Random Number, Blinding description: 1. The participants, while aware that the placebo and two Donepezil and Rivastigmine drugs were used in this study, were unaware of the medicine being given to them. 2. In this study, the researcher does not know how each participant is undergoing treatment. 3 EcT in patients with Mood Disorders. Intervention 1: Intervention group: Tablet Donepezil 5 mg daily for 2 weeks. Intervention 2: Intervention group: Cap Rivastigmine 1.5 mg twice a day for one week and 3 mg twice a day until the end of study. Intervention 3: Control group: Placebo. Yes - There is a plan to make this available What will be shared: Some of the data could be shared. When: It would be available 6 months after publication of the results To whom: University Researchers Conditions: For research and treatment issues Where to obtain: To published article How to obtain: Journal's website Comments:
public Masoumeh Nazarinasab
Golestan Hospital, Ahvaz Joundishapour University of Medical Sciences, Golestan
Ahvaz Iran (Islamic Republic of) 6135733118 +98 61337430011 Nazarinasab-m@ajums.ac.ir Ahvaz University of Medical Sciences scientific Masoumeh Nazarinasab
Golestan Hospital, Ahvaz Joundishapour University of Medical Sciences, Golestan
Ahvaz Iran (Islamic Republic of) 6135733118 +98 61337430011 Nazarinasab-m@ajums.ac.ir Ahvaz University of Medical Sciences Iran (Islamic Republic of) Schizophrenia Disorder Schizoaffective Disorder Bipolar Mood Disorder Major Depressive Disorder ECT 6-12 Sessions 18 years 60 years Both F31 Bipolar affective disorder Other Other Other Intervention group: Tablet Donepezil 5 mg daily for 2 weeks Intervention group: Cap Rivastigmine 1.5 mg twice a day for one week and 3 mg twice a day until the end of study Control group: Placebo Evaluation of cognitive function by MMSE. Timepoint: In the first, middle and end of the period of ECT Therapy. Method of measurement: MMSE. Ahvaz University of Medical Sciences Approved 2017-11-11 Ethics committee of Ahvaz University of Medical Sciences Golestan Hospital, Ahvaz Joundishapour University of Medical Sciences, Golestan Ahvaz Khouzestan Iran (Islamic Republic of)